FDA Approves Jardiance (empagliflozin) to Reduce Cardiovascu
The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease.


“Cardiovascular disease is a leading cause of death in adults with type 2 diabetes mellitus,” said Jean-Marc Guettier, M.D., C.M., director of the Division of Metabolism and Endocrinology Products in FDA’s Center for Drug Evaluation and Research. “Availability of antidiabetes therapies that can help people live longer by reducing the risk of cardiovascular death is an important advance for adults with type 2 diabetes.”....

https://www.drugs.com/newdrugs/fda-approves-jardiance-empagliflozin-reduce-cardiovascular-death-adults-type-2-diabetes-4462.html
Like
Comment
Share